Clinical Significance of Complement and Coagulation Cascades Genes for Patients With Acute Lymphoblastic Leukemia
Yuting Tang
Laboratory of Radiation Biology, Department of Blood Transfusion, Laboratory Medicine Center, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Laboratory of Precision Medicine, Department of Blood Transfusion, Laboratory Medicine Center, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Search for more papers by this authorLi Chen
Laboratory of Radiation Biology, Department of Blood Transfusion, Laboratory Medicine Center, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Laboratory of Precision Medicine, Department of Blood Transfusion, Laboratory Medicine Center, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Hematopoietic Acute Radiation Syndrome Medical and Pharmaceutical Basic Research Innovation Center, Ministry of Education of the People's Republic of China, Laboratory Medicine Center, Department of Blood Transfusion, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Search for more papers by this authorYanni Xiao
Laboratory of Radiation Biology, Department of Blood Transfusion, Laboratory Medicine Center, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Hematopoietic Acute Radiation Syndrome Medical and Pharmaceutical Basic Research Innovation Center, Ministry of Education of the People's Republic of China, Laboratory Medicine Center, Department of Blood Transfusion, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Search for more papers by this authorQian Ran
Laboratory of Radiation Biology, Department of Blood Transfusion, Laboratory Medicine Center, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Hematopoietic Acute Radiation Syndrome Medical and Pharmaceutical Basic Research Innovation Center, Ministry of Education of the People's Republic of China, Laboratory Medicine Center, Department of Blood Transfusion, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Search for more papers by this authorCorresponding Author
Zhongjun Li
Laboratory of Radiation Biology, Department of Blood Transfusion, Laboratory Medicine Center, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Laboratory of Precision Medicine, Department of Blood Transfusion, Laboratory Medicine Center, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Hematopoietic Acute Radiation Syndrome Medical and Pharmaceutical Basic Research Innovation Center, Ministry of Education of the People's Republic of China, Laboratory Medicine Center, Department of Blood Transfusion, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Correspondence:
Zhongjun Li ([email protected])
Maoshan Chen ([email protected])
Search for more papers by this authorCorresponding Author
Maoshan Chen
Laboratory of Radiation Biology, Department of Blood Transfusion, Laboratory Medicine Center, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Laboratory of Precision Medicine, Department of Blood Transfusion, Laboratory Medicine Center, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Hematopoietic Acute Radiation Syndrome Medical and Pharmaceutical Basic Research Innovation Center, Ministry of Education of the People's Republic of China, Laboratory Medicine Center, Department of Blood Transfusion, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Correspondence:
Zhongjun Li ([email protected])
Maoshan Chen ([email protected])
Search for more papers by this authorYuting Tang
Laboratory of Radiation Biology, Department of Blood Transfusion, Laboratory Medicine Center, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Laboratory of Precision Medicine, Department of Blood Transfusion, Laboratory Medicine Center, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Search for more papers by this authorLi Chen
Laboratory of Radiation Biology, Department of Blood Transfusion, Laboratory Medicine Center, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Laboratory of Precision Medicine, Department of Blood Transfusion, Laboratory Medicine Center, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Hematopoietic Acute Radiation Syndrome Medical and Pharmaceutical Basic Research Innovation Center, Ministry of Education of the People's Republic of China, Laboratory Medicine Center, Department of Blood Transfusion, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Search for more papers by this authorYanni Xiao
Laboratory of Radiation Biology, Department of Blood Transfusion, Laboratory Medicine Center, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Hematopoietic Acute Radiation Syndrome Medical and Pharmaceutical Basic Research Innovation Center, Ministry of Education of the People's Republic of China, Laboratory Medicine Center, Department of Blood Transfusion, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Search for more papers by this authorQian Ran
Laboratory of Radiation Biology, Department of Blood Transfusion, Laboratory Medicine Center, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Hematopoietic Acute Radiation Syndrome Medical and Pharmaceutical Basic Research Innovation Center, Ministry of Education of the People's Republic of China, Laboratory Medicine Center, Department of Blood Transfusion, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Search for more papers by this authorCorresponding Author
Zhongjun Li
Laboratory of Radiation Biology, Department of Blood Transfusion, Laboratory Medicine Center, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Laboratory of Precision Medicine, Department of Blood Transfusion, Laboratory Medicine Center, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Hematopoietic Acute Radiation Syndrome Medical and Pharmaceutical Basic Research Innovation Center, Ministry of Education of the People's Republic of China, Laboratory Medicine Center, Department of Blood Transfusion, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Correspondence:
Zhongjun Li ([email protected])
Maoshan Chen ([email protected])
Search for more papers by this authorCorresponding Author
Maoshan Chen
Laboratory of Radiation Biology, Department of Blood Transfusion, Laboratory Medicine Center, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Laboratory of Precision Medicine, Department of Blood Transfusion, Laboratory Medicine Center, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Hematopoietic Acute Radiation Syndrome Medical and Pharmaceutical Basic Research Innovation Center, Ministry of Education of the People's Republic of China, Laboratory Medicine Center, Department of Blood Transfusion, the Second Affiliated Hospital, Army Medical University, Chongqing, China
Correspondence:
Zhongjun Li ([email protected])
Maoshan Chen ([email protected])
Search for more papers by this authorFunding: This work was supported by the Chongqing Key Program of Natural Science Foundation (CSTC2020JCYJ-ZDXMX0013), Chongqing Natural Science Foundation (CSTB2022NSCQ-MSX0190), and Xinqiao Young Postdoc Talent Incubation Program (2022YQB042).
ABSTRACT
Introduction
Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults and the 5-year survival remains low.
Methods
We analyzed the gene expression profiles of the complement and coagulation cascades pathway (CCCP) in 998 bone marrow (BM) and 122 peripheral blood (PB) samples of ALL patients and healthy individuals obtained from the TCGA database and evaluated their clinical significance in terms of being diagnostic and prognostic biomarkers.
Results
We identified 18 CCCP genes (SERPINA1, C5AR1, F5, CD55, PLAUR, C3AR1, THBD, CD59, PLAU, VWF, CFD, F13A1, C1QA, C1QB, C1QC, A2M, SERPINE1 and CR2) differentially expressed in the BM samples of ALL patients compared to healthy individuals. The expression levels of CD55, F13A1 and CR2 in BM were linked with the overall survival of ALL patients. While in PB only 11 CCCP genes (e.g., SERPINA1, C5AR1, F5, PLAUR, C3AR1, THBD, CFD, F13A1, C1QA, SERPINE1, and CR2) were differentially expressed and F13A1 was significantly associated with ALL patient survival. Machine learning enabled us to predict ALL using the CCCP genes and the accuracy can reach 0.9701 and 0.9167 using the BM and PB, respectively. Furthermore, using single-cell RNA sequencing, we found that the differential expression of CCCP genes was found with diversity in the BM-derived immune cells of ALL patients.
Conclusion
Our findings suggest that the CCCP genes may play a key role in the progression of ALL and can be used as potential therapeutic targets and diagnostic markers.
Conflicts of Interest
The authors declare no conflicts of interest.
Open Research
Data Availability Statement
The gene expression profiles of BM and PB samples of ALL patients can be accessed on the TCGA website (https://portal.gdc.cancer.gov); the gene expression microarray data of BM samples of ALL patients can be accessed from the NCBI GEO platform via the accession number GSE128254; and the raw expression matrix data of single-cell RNA sequencing data for BM-derived immune cells of ALL patients can be accessed from the NCBI GEO platform via the accession number GSE130116.
Supporting Information
| Filename | Description |
|---|---|
| ijlh14392-sup-0001-supinfo.xlsxExcel 2007 spreadsheet , 9.9 KB |
Data S1. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1 F. Malard and M. Mohty, “Acute Lymphoblastic Leukaemia,” Lancet 395, no. 10230 (2020): 1146–1162.
- 2 L. Pagliaro, S. J. Chen, D. Herranz, et al., “Acute Lymphoblastic Leukaemia,” Nature Reviews. Disease Primers 10, no. 1 (2024): 41.
- 3 H. Newman and S. P. Hunger, “Future of Treatment of Adolescents and Young Adults With ALL: A Vision for Collaboration and Equity,” Journal of Clinical Oncology 42, no. 6 (2024): 665–674.
- 4 W. Olejarz, K. Sadowski, D. Szulczyk, and G. Basak, “Advancements in Personalized CAR-T Therapy: Comprehensive Overview of Biomarkers and Therapeutic Targets in Hematological Malignancies,” International Journal of Molecular Sciences 25, no. 14 (2024): 7743.
- 5 S. Luo, M. Wang, H. Wang, D. Hu, P. F. Zipfel, and Y. Hu, “How Does Complement Affect Hematological Malignancies: From Basic Mechanisms to Clinical Application,” Frontiers in Immunology 11 (2020): 593610.
- 6 E. S. Reis, D. C. Mastellos, D. Ricklin, A. Mantovani, and J. D. Lambris, “Complement in Cancer: Untangling an Intricate Relationship,” Nature Reviews. Immunology 18, no. 1 (2018): 5–18.
- 7 D. Ajona, S. Ortiz-Espinosa, H. Moreno, et al., “A Combined PD-1/C5a Blockade Synergistically Protects Against Lung Cancer Growth and Metastasis,” Cancer Discovery 7, no. 7 (2017): 694–703.
- 8 Y. Wang, S. N. Sun, Q. Liu, et al., “Autocrine Complement Inhibits IL10-Dependent T-Cell-Mediated Antitumor Immunity to Promote Tumor Progression,” Cancer Discovery 6, no. 9 (2016): 1022–1035.
- 9 H. Zha, X. Han, Y. Zhu, et al., “Blocking C5aR Signaling Promotes the Anti-Tumor Efficacy of PD-1/PD-L1 Blockade,” Oncoimmunology 6, no. 10 (2017): e1349587.
- 10 M. M. Markiewski, R. A. DeAngelis, F. Benencia, et al., “Modulation of the Antitumor Immune Response by Complement,” Nature Immunology 9, no. 11 (2008): 1225–1235.
- 11 J. Ma, L. Liu, G. Che, N. Yu, F. Dai, and Z. You, “The M1 Form of Tumor-Associated Macrophages in Non-small Cell Lung Cancer Is Positively Associated With Survival Time,” BMC Cancer 10 (2010): 112.
- 12 S. R. Dannenmann, J. Thielicke, M. Stockli, et al., “Tumor-Associated Macrophages Subvert T-Cell Function and Correlate With Reduced Survival in Clear Cell Renal Cell Carcinoma,” Oncoimmunology 2, no. 3 (2013): e23562.
- 13 M. S. Cho, H. G. Vasquez, R. Rupaimoole, et al., “Autocrine Effects of Tumor-Derived Complement,” Cell Reports 6, no. 6 (2014): 1085–1095.
- 14 A. K. Singh and R. Malviya, “Coagulation and Inflammation in Cancer: Limitations and Prospects for Treatment,” Biochimica Et Biophysica Acta. Reviews on Cancer 1877, no. 3 (2022): 188727.
- 15 J. Zhang, M. Chen, Y. Zhao, et al., “Complement and Coagulation Cascades Pathway Correlates With Chemosensitivity and Overall Survival in Patients With Soft Tissue Sarcoma,” European Journal of Pharmacology 879 (2020): 173121.
- 16 J. Yang, L. Shen, J. Yang, et al., “Complement and Coagulation Cascades Are Associated With Prognosis and the Immune Microenvironment of Lower-Grade Glioma,” Translational Cancer Research 13, no. 1 (2024): 112–136.
- 17 J. Jantaravinid, N. Tirawanchai, S. Ampawong, et al., “Transcriptomic Screening of Novel Targets of Sericin in Human Hepatocellular Carcinoma Cells,” Scientific Reports 14, no. 1 (2024): 5455.
- 18 Z. Gong, Y. He, X. Mi, et al., “Complement and Coagulation Cascades Pathway-Related Signature as a Predictor of Immunotherapy in Metastatic Urothelial Cancer,” Aging (Albany NY) 15, no. 18 (2023): 9479–9498.
- 19 I. Laverdiere, M. Boileau, T. Herold, et al., “Complement Cascade Gene Expression Defines Novel Prognostic Subgroups of Acute Myeloid Leukemia,” Experimental Hematology 44, no. 11 (2016): 1039–1043.
- 20 M. Ghaderzadeh, M. Aria, A. Hosseini, F. Asadi, D. Bashash, and H. Abolghasemi, “A Fast and Efficient CNN Model for B-ALL Diagnosis and Its Subtypes Classification Using Peripheral Blood Smear Images,” International Journal of Intelligent Systems 37, no. 8 (2022): 5113–5133.
- 21 M. Ghaderzadeh, A. Hosseini, F. Asadi, H. Abolghasemi, D. Bashash, and A. Roshanpoor, “Automated Detection Model in Classification of B-Lymphoblast Cells From Normal B-Lymphoid Precursors in Blood Smear Microscopic Images Based on the Majority Voting Technique,” Scientific Programming 2022 (2022): 4801671.
- 22
A. Hosseini, M. A. Eshraghi, T. Taami, et al., “A Mobile Application Based on Efficient Lightweight CNN Model for Classification of B-ALL Cancer From Non-cancerous Cells: A Design and Implementation Study,” Informatics in Medicine Unlocked 39 (2023): 101244.
10.1016/j.imu.2023.101244 Google Scholar
- 23 M. Chen, R. Xu, A. Rai, et al., “Distinct Shed Microvesicle and Exosome microRNA Signatures Reveal Diagnostic Markers for Colorectal Cancer,” PLoS One 14, no. 1 (2019): e0210003.
- 24 M. T. Witkowski, I. Dolgalev, N. A. Evensen, et al., “Extensive Remodeling of the Immune Microenvironment in B Cell Acute Lymphoblastic Leukemia,” Cancer Cell 37, no. 6 (2020): 867–882.
- 25 P. K. Gruninger, F. Uhl, H. Herzog, et al., “Functional Characterization of the PI3K/AKT/MTOR Signaling Pathway for Targeted Therapy in B-Precursor Acute Lymphoblastic Leukemia,” Cancer Gene Therapy 29, no. 11 (2022): 1751–1760.
- 26 A. Ghelli Luserna Di Rora, M. Ghetti, L. Ledda, et al., “Exploring the ATR-CHK1 Pathway in the Response of Doxorubicin-Induced DNA Damages in Acute Lymphoblastic Leukemia Cells,” Cell Biology and Toxicology 39, no. 3 (2023): 795–811.
- 27 A. T. Bauer, C. Gorzelanny, C. Gebhardt, K. Pantel, and S. W. Schneider, “Interplay Between Coagulation and Inflammation in Cancer: Limitations and Therapeutic Opportunities,” Cancer Treatment Reviews 102 (2022): 102322.
- 28 C. M. de Bont, W. C. Boelens, and G. J. M. Pruijn, “NETosis, Complement, and Coagulation: A Triangular Relationship,” Cellular & Molecular Immunology 16, no. 1 (2019): 19–27.
- 29 J. Dong, F. Zheng, F. Liu, et al., “Global-Feature of Autoimmune Glomerulonephritis Using Proteomic Analysis of Laser Capture Microdissected Glomeruli,” Frontiers in Immunology 14 (2023): 1131164.
- 30 Y. Ma, Y. Chen, L. Zhan, et al., “CEBPB-Mediated Upregulation of SERPINA1 Promotes Colorectal Cancer Progression by Enhancing STAT3 Signaling,” Cell Death Discovery 10, no. 1 (2024): 219.
- 31 J. Zhao, C. Yao, Y. Qin, et al., “Blockade of C5aR1 Resets M1 via Gut Microbiota-Mediated PFKM Stabilization in a TLR5-Dependent Manner,” Cell Death & Disease 15, no. 2 (2024): 120.
- 32 S. Cavalcante Mde, J. C. Torres-Romero, M. D. Lobo, et al., “A Panel of Glycoproteins as Candidate Biomarkers for Early Diagnosis and Treatment Evaluation of B-Cell Acute Lymphoblastic Leukemia,” Biomarker Research 4 (2016): 1.
- 33 M. M. Duplantier, L. Lamant, F. Sabourdy, A. de Reynies, G. Delsol, and E. Espinos, “Serpin A1 Is Overexpressed in ALK+ Anaplastic Large Cell Lymphoma and Its Expression Correlates With Extranodal Dissemination,” Leukemia 20, no. 10 (2006): 1848–1854.
- 34 S. Chen, Y. Li, Y. Zhu, et al., “SERPINE1 Overexpression Promotes Malignant Progression and Poor Prognosis of Gastric Cancer,” Journal of Oncology 2022 (2022): 2647825.
- 35 L. Li, F. Li, Z. Xu, et al., “Identification and Validation of SERPINE1 as a Prognostic and Immunological Biomarker in Pan-Cancer and in ccRCC,” Frontiers in Pharmacology 14 (2023): 1213891.
- 36 L. E. Bradbury, G. S. Kansas, S. Levy, R. L. Evans, and T. F. Tedder, “The CD19/CD21 Signal Transducing Complex of Human B Lymphocytes Includes the Target of Antiproliferative Antibody-1 and Leu-13 Molecules,” Journal of Immunology 149, no. 9 (1992): 2841–2850.
- 37 A. Franco, Z. Kraus, H. Li, N. Seibert, J. Dement-Brown, and M. Tolnay, “CD21 and FCRL5 Form a Receptor Complex With Robust B-Cell Activating Capacity,” International Immunology 30, no. 12 (2018): 569–578.
- 38 H. Z. Low, D. Hilbrans, I. G. Schmidt-Wolf, and H. Illges, “Enhanced CD21 Expression and Shedding in Chronic Lymphatic Leukemia: A Possible Pathomechanism in Disease Progression,” International Journal of Hematology 96, no. 3 (2012): 350–356.
- 39 A. Santagostino, L. Lombardi, G. Dine, P. Hirsch, and S. C. Misra, “Paroxysmal Nocturnal Hemoglobinuria With a Distinct Molecular Signature Diagnosed Ten Years After Allogenic Bone Marrow Transplantation for Acute Myeloid Leukemia,” Case Reports in Hematology 2019 (2019): 8928623.
- 40 J. Meletis, E. Terpos, M. Samarkos, et al., “Red Cells With Paroxysmal Nocturnal Hemoglobinuria-Phenotype in Patients With Acute Leukemia,” Hematology 7, no. 2 (2002): 69–74.
- 41 K. Gyurina, B. Karai, A. Ujfalusi, et al., “Coagulation FXIII-A Protein Expression Defines Three Novel Sub-Populations in Pediatric B-Cell Progenitor Acute Lymphoblastic Leukemia Characterized by Distinct Gene Expression Signatures,” Frontiers in Oncology 9 (2019): 1063.
- 42 C. Kiss, K. Gyurina, G. Kiss, et al., “Expression Level of A Coagulation Factor Gene, F13A1 Defines Characteristic Subpopulations of Childhood Acute Lymphoblastic Leukemia,” Blood 122, no. 21 (2013): 4888.
- 43 K. Dull, F. Fazekas, and D. Törőcsik, “Factor XIII-A in Diseases: Role Beyond Blood Coagulation,” International Journal of Molecular Sciences 22, no. 3 (2021): 1459.
- 44 J. Marrugo-Ramirez, M. Mir, and J. Samitier, “Blood-Based Cancer Biomarkers in Liquid Biopsy: A Promising Non-Invasive Alternative to Tissue Biopsy,” International Journal of Molecular Sciences 19, no. 10 (2018): 2877.
- 45 D. A. Arber, A. Orazi, R. Hasserjian, et al., “The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia,” Blood 127, no. 20 (2016): 2391–2405.
- 46 G. Lin, W. Chen, Y. Fan, et al., “Machine Learning Radiomics-Based Prediction of Non-sentinel Lymph Node Metastasis in Chinese Breast Cancer Patients With 1-2 Positive Sentinel Lymph Nodes: A Multicenter Study,” Academic Radiology 31 (2024): 3081–3095.
- 47 M. Zuckerbrot-Schuldenfrei, S. Aviel-Ronen, A. Zilberberg, and S. Efroni, “Ovarian Cancer Is Detectable From Peripheral Blood Using Machine Learning Over T-Cell Receptor Repertoires,” Briefings in Bioinformatics 25, no. 2 (2024): bbae075.
